A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.

IF 0.8 Q4 RESPIRATORY SYSTEM

Respirology Case Reports Pub Date : 2025-09-29 eCollection Date: 2025-10-01 DOI:10.1002/rcr2.70352

Yuma Tanaka, Naoya Ikegami, Kodai Miyamoto, Yusuke Shingu, Nobuhiro Okagaki, Hiroto Sakamoto, Tsukasa Nakanishi, Satoshi Nakamura, Kazuki Matsumura, Masakuni Ueyama, Yusuke Kaji, Seishu Hashimoto, Eisaku Tanaka, Yoshio Taguchi, Yuki Ohsumi, Tatsuo Nakagawa, Satoshi Matsunaga, Takashi Hajiro

{"title":"A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.","authors":"Yuma Tanaka, Naoya Ikegami, Kodai Miyamoto, Yusuke Shingu, Nobuhiro Okagaki, Hiroto Sakamoto, Tsukasa Nakanishi, Satoshi Nakamura, Kazuki Matsumura, Masakuni Ueyama, Yusuke Kaji, Seishu Hashimoto, Eisaku Tanaka, Yoshio Taguchi, Yuki Ohsumi, Tatsuo Nakagawa, Satoshi Matsunaga, Takashi Hajiro","doi":"10.1002/rcr2.70352","DOIUrl":null,"url":null,"abstract":"<p><p>An 80-year-old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy. The oncogene panel test showed a positive RET-fusion gene mutation, and selpercatinib was administered as a first-line treatment. She developed severe hyponatremia and was subsequently diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Discontinuing selpercatinib and initiating demethyltetracycline gradually improved SIADH. After confirming that sodium levels had returned to normal, we resumed and continued selpercatinib at a reduced dose without a recurrence of SIADH. This case suggests that selpercatinib could cause SIADH as an adverse event.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"13 10","pages":"e70352"},"PeriodicalIF":0.8000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479716/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

An 80-year-old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy. The oncogene panel test showed a positive RET-fusion gene mutation, and selpercatinib was administered as a first-line treatment. She developed severe hyponatremia and was subsequently diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Discontinuing selpercatinib and initiating demethyltetracycline gradually improved SIADH. After confirming that sodium levels had returned to normal, we resumed and continued selpercatinib at a reduced dose without a recurrence of SIADH. This case suggests that selpercatinib could cause SIADH as an adverse event.

查看原文本刊更多论文

Selpercatinib致RET融合基因阳性非小细胞肺癌患者抗利尿激素分泌异常综合征1例。

一位80岁的妇女，右下叶有肺结节，胸膜增厚，经手术肺活检诊断为肺腺癌。癌基因面板测试显示ret融合基因突变阳性，并给予selpercatinib作为一线治疗。她出现严重的低钠血症，随后被诊断为抗利尿激素分泌不当综合征。停用selpercatinib并开始使用去甲基四环素逐渐改善SIADH。在确认钠水平恢复正常后，我们恢复并继续使用减少剂量的自泊替尼，没有复发SIADH。本病例提示selpercatinib可能作为不良事件导致SIADH。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.